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Moreover, in vivo, silencing of β-arr1 ormacitentan treatment inhibited
metastasis in sensitive and resistant EOC xenografts, providing evi-
dence that blockade of ETAR/β-arr1-driven EMT can overcome chemo-
resistance and inhibit tumor progression. Collectively, our ﬁndings
provide insights into how ETAR controls EMT transcriptional responses
and tumor initiating trait, deciphering a novel function for β-arr1
for nuclear compartmentalization of ETAR signalling inﬂuencing the
mechanism of acquired resistance, EMT and stem-cell like features.
doi:10.1016/j.lfs.2013.12.053
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The endothelin system is an important paracrine or autocrine
system for cancer cell proliferation. Endothelin-1 and endothelin
receptors are expressed in various types of cancers including breast
cancer. (Pro)renin receptor ((P)RR) is a speciﬁc receptor for renin and
prorenin. Receptor-bound prorenin becomes enzymatically active in
converting angiotensinogen to angiotensin I, and binding then activates
phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2),
independent of angiotensin II generation. Furthermore, (P)RR is asso-
ciated with vacuolar-type H+-ATPase (V-ATPase), which may be
related to cell proliferation. The aim of the present study is to clarify
the pathophysiological role of (P)RR in breast cancer. We investigated
(P)RR expression in 69 clinical cases of breast carcinoma by immuno-
histochemistry and its correlation with clinicopathological parameters.
Effects of (P)RR on cell proliferation and ERK1/2 phosphorylation
were examined in cultured human breast carcinoma cells. Immuno-
histochemistry showed that (P)RR immunoreactivity was detected
in carcinoma cells of breast carcinoma tissues, and was correlated
with Ki-67 expression. The (P)RR speciﬁc small interference RNA or
baﬁlomycin A1 (an inhibitor of V-ATPase activity) inhibited cell growth
of breast carcinoma cell lines (MCF-7 and SK-BR-3). Prorenin stimulat-
ed the phosphorylation of ERK1/2 in MCF-7 cells. Treatment of MCF-7
cells with endothelin-1 had no signiﬁcant effects on (P)RR expression
levels. The present study has raised the possibility that, in addition
to the endothelin system, (P)RR is involved in the pathophysiology of
breast cancer by stimulating the proliferation of breast carcinoma cells
via the association of V-ATPase and/or phosphorylation of ERK1/2.
doi:10.1016/j.lfs.2013.12.054
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Poly-gamma-glutamic acid (PGA), naturally secreted from various
strains of Bacillus, has anti-inﬂammatory activity. In inﬂammatory
bowel disease (IBD), inﬂammation is promoted and sustained by
angiogenesis; however, the role played by PGA in this condition is
unclear. Therefore, we evaluated PGA effects on angiogenesis and
inﬂammation in a dextran sulfate sodium (DSS)-induced mouse
colitis model. Experimental colitis was induced in male C57BL/6 mice
by administering 3% DSS. Disease activity index (DAI), histopatho-
logical scores, microvascular density, myeloperoxidase activity, and
VEGF-A and VEGFR2 expression were compared among control mice,
DSS-treated mice, and mice receiving 3% DSS along with PGA at
50 mg/kg body weight per day, or 3% DSS with PGA at 200 mg/kg
body weight per day. We found that PGA signiﬁcantly attenuated
weight loss, DAI, and colon shortening. PGA also signiﬁcantly re-
duced histopathological evidence of injury. Moreover, PGA signiﬁ-
cantly attenuated DSS-induced blood vessel densities. Furthermore,
PGA attenuated DSS-induced expression of VEGF-A and its receptor,
VEGFR2. In addition, PGA treatment led to reduced recruitment of
leukocytes to the inﬂamed colon. Therefore, our results indicate that
PGA has potential application in conditions marked by inﬂammatory-
driven angiogenesis and mucosal inﬂammation.
doi:10.1016/j.lfs.2013.12.055
Identiﬁcation of bladder endothelin-1 receptors and binding
characteristics of bosentan and ambrisentan
Ayaka Osano
Pharmacokinetics and Pharmacodynamics, Japan
Clinical Pharmacology and Genetics, Japan
E-mail address: s12134@u-shizuoka-ken.ac.jp (A. Osano)
Endothelin (ET)-1 induces prolonged contractile responses in
isolated bladder muscle strips. ET-like immunoreactivity was identiﬁed
in detrusor muscles, epithelium and vascular endothelium. Selective
ETA receptor antagonists have ameliorating effects on urinary dysfunc-
tions. The current study aimed to identify bladder ET-1 receptors using
radioligand binding assay and characterize receptor binding of clinically
used ET-1 receptor antagonists. ET-1 receptors were measured in
rat bladder using [125I]ET-1, and binding parameters of dissociation
constant (Kd), and the maximal number of binding sites (Bmax) for
[125I]ET-1were estimated. The inhibition of speciﬁc [125I]ET-1 binding
was measured in the presence of ET-1 and its receptor antagonists.
Speciﬁc [125I]ET-1 binding in rat bladder was saturable and of high
afﬁnity, which characterized selective labeling of bladder ET-1 recep-
tors. ET-1, bosentan, ambrisentan, and CI-1020 inhibited speciﬁc [125I]
ET-1 binding in a concentration-dependent manner at nanomolar
ranges of IC50. Nonlinear least squares regression analysis revealed the
presence of high- and low-afﬁnity ET-1 receptor sites for ambrisentan
and CI-1020. Bosentan signiﬁcantly increased Kd for bladder [125I]ET-1
binding without affecting Bmax, while ambrisentan increased Kd
with a concomitant reduction in Bmax. Thus, bosentan seems to bind
bladder ET-1 receptor in a competitive and reversible manner while
ambrisentan may bind to bladder ET-1 receptors, partially in a non-
competitive manner in addition to a competitive manner. Oral admin-
istration of bosentan caused a dose-dependent decrease in Bmax for
bladder [125I]ET-1 binding, suggesting signiﬁcant binding of bladder
ET-1 receptors in vivo. These results indicate that pharmacologically
relevant ET-1 receptors exist in rat bladder and they may become a
promising target for the development of novel therapeutic agents for
bladder dysfunction.
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